SciVision Biotech's (TPE:1786) one-injection and three-injection hyaluronic acid synovial fluid products obtained medical device licenses in Panama, according to a Friday Taiwan Exchange filing.
The products, FLEXVISC PLUS and FLEXVISC, improve joint lubrication and reduce friction. They also help relieve osteoarthritis pain and improve mobility, the company said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.